Oncology

Cancer touches the lives of millions of people around the world, and we know there is urgency to act. At Lantheus, we are dedicated to transforming cancer care by investigating next-generation radiodiagnostics and precision radiotherapeutics that enable both early and accurate detection and the ability to fight disease at the source.

The Role of Radiopharmaceuticals in Cancer Care

Radiopharmaceuticals have played a vital role in cancer care for over a century, serving as a foundational diagnostic and therapeutic tool. Yet cancer continues to be a leading cause of death worldwide. At Lantheus, we understand that patients deserve more—more clarity when receiving a diagnosis and more options to treat disease.

1 in 3 people In the U.S. will receive a cancer diagnosis in their life1

people in the U.S. will be diagnosed with cancer in 20252

Oncology Focus Areas

We are advancing a diverse pipeline of potential next-generation radiodiagnostics and precision radiotherapeutics that, as potential theranostic pairs, could deliver best- and first-in-class opportunities in disease areas with high unmet need.

Prostate Cancer

Prostate cancer is the second most common cancer in American men.3 Lantheus is committed to following the science across multiple targets in our efforts to develop groundbreaking radioligand therapies and radiodiagnostic tracers, focusing on prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).

Neuroendocrine Tumors (NETs)

NETs can arise in any organ, vary widely in form and behavior and can be rare and often difficult to diagnose.4 We’re developing a radiodiagnostic for NETs and taking a theranostic approach to explore potential radiodiagnostic and radiotherapeutic options for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Read More

Other Solid Tumors

Our pipeline encompasses several innovations for potentially diagnosing and treating a range of solid tumors like small cell lung cancer, glioblastoma, osteosarcoma, pancreatic ductal adenocarcinoma and lobular breast cancer.

A New Frontier in Molecular Imaging and Therapeutic Options

Lantheus is committed to unlocking the full potential of radiopharmaceuticals, generating novel targets through our early development engine, advancing pre-clinical radiotheranostic programs and testing potential assets in cancers with high unmet need.

Molecular Imaging for Cancer

Imaging modalities like positron emission tomography (PET) have revolutionized cancer diagnosis, staging and monitoring. Low-dose radiotracers bind to select tissues, opening up the possibility for  tailored treatment strategies and monitoring opportunities.5

Precision Cancer Treatment

Radiotherapeutics have emerged as a powerful modality in cancer treatment. Radioligand therapies (RLTs) bind to antigens or receptors that overexpress on the surface of certain cancer cells, allowing radiotherapeutics to more specifically seek and destroy them while sparing healthy tissue.6

The Emergence of Theranostic Solutions

Theranostics are a groundbreaking approach, combining a radiodiagnostic with a radiotherapeutic to selectively target and destroy cancer cells while minimizing damage to healthy tissues. They offer a promising solution for patients with hard-to-treat cancers.

References: 1. Lifetime Risk of Developing or Dying From Cancer. American Cancer Society. Accessed May 21, 2025. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/lifetime-probability-of-developing-or-dying-from-cancer.html 2. Cancer Stat Facts: Common Cancer Sites. National Cancer Institute. Accessed May 21, 2025. https://seer.cancer.gov/statfacts/html/common.html 3. Cancer Facts for Men. American Cancer Society. Accessed May 21, 2025. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/lifetime-probability-of-developing-or-dying-from-cancer.html 4. A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management. National Library of Medicine. Published August 5, 2023. Accessed May 21, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC10420169/ 5. Use of PET/CT scanning in cancer patients: technical and practical considerations. National Library of Medicine. Published October 18, 2005. Accessed May 21, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC1255942/ 6. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. National Library of Medicine. Published June 14, 2023. Accessed May 21, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC10303056/